Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke.
BACKGROUND
The aim of this study was to examine the rate of early neurological deterioration (END) and favorable outcomes after acute lacunar stroke following the use of intravenous recombinant tissue plasminogen activator (IV rtPA).


METHODS
A total of 76 acute lacunar stroke patients (<12 h from symptom onset) were enrolled during a 1-year period (n = 76). Comparisons were made between those who received (group A; n = 29) or did not receive (group B; n = 47) IV rtPA.


RESULTS
END/favorable outcomes were observed in 24/31% of the subjects in group A and 21/23% in group B (p = 0.77/0.46). Subgroup analysis of the etiologic subtype of small-vessel occlusion showed that END/favorable outcomes were observed in about 33/33% and 15/19% of the patients in groups A and B, respectively (p = 0.21/0.34).


CONCLUSIONS
The authors showed that the use of rtPA in cases of no lysible clots might not affect the END and favorable outcomes.
Hwang
Yang-Ha
YH
Department of Neurology, Kyungpook National University Hospital, Daegu, South Korea. Yangha.Hwang@gmail.com
Seo
Jong-Geun
JG
Lee
Ho-Won
HW
Park
Sung-Pa
SP
Suh
Chung-Kyu
CK
D000208:Acute Disease; D000368:Aged; D020520:Brain Infarction / Q000401:mortality* / Q000473:pathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D020521:Stroke / Q000401:mortality* / Q000473:pathology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator